Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of raltegravir vs darunavir/cobicistat plus TAF/FTC in HIV patients with low CD4 counts
2017-003470-14Phase 4Active
- Sponsor
- Fundación IMABIS
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in human immunodeficiency virus infection (HIV) comparing Raltegravir + TAF/FTC with Darunavir/cobicistat + TAF/FTC (2 arms). Primary endpoint: Virologic suppression at week 48. Started Sep 2018; status: active.
02
Drugs
raltegravirdarunavircobicistattenofovir alafenamideemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-003470-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003470-14.